LIFE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 12:18):

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States...

Stats
Today's Volume	158 882
Average Volume	556 808
Market Cap	108.06M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.240 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.700
ATR14	$0.00600 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-05	Shukla Sanjay	Buy	10 375	Common stock
2024-02-05	Shukla Sanjay	Sell	10 375	Restricted Stock Unit
2024-02-05	Broadfoot Jill Marie	Buy	3 750	Common stock
2024-02-06	Broadfoot Jill Marie	Sell	1 590	Common stock
2024-02-05	Broadfoot Jill Marie	Sell	3 750	Restricted Stock Unit

INSIDER POWER
92.97
Last 99 transactions
Buy: 4 079 228 \| Sell: 350 127

Volume Correlation

Long: -0.28 (neutral)

Short: 0.00 (neutral)

Signal:(38.056) Neutral

aTyr Pharma Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations
TYHT	-0.821

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

aTyr Pharma Inc Correlation - Currency/Commodity

-0.69
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

0.00
( neutral )

0.56
( weak )

aTyr Pharma Inc Financials

Annual	2023
Revenue:	$353 000
Gross Profit:	$-2.39M (-676.49 %)
EPS:	$-0.940

Q4	2023
Revenue:	$0
Gross Profit:	$-407 000 (0.00 %)
EPS:	$-0.250

Q3	2023
Revenue:	$353 000
Gross Profit:	$-640 000 (-181.30 %)
EPS:	$-0.200

Q2	2023
Revenue:	$0
Gross Profit:	$-586 000 (0.00 %)
EPS:	$-0.220

Financial Reports:

No articles found.

aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.